Olayan Financing invests in MS Pharma
Analysis based on 7 articles · First reported May 18, 2026 · Last updated May 18, 2026
The investment by Olayan Financing Company in Lewis Pharmacy is expected to boost Lewis Pharmacy's growth, particularly in the biosimilars market across the Europe, the Middle East and Africa region, potentially increasing its market share and revenue. This strategic partnership also signals increased investment confidence in the pharmaceutical sector within Saudi Arabia, aligning with its Saudi Vision 2030 goals for economic diversification and local content.
Lewis Pharmacy announced that Olayan Financing Company (OFC) has made a minority equity investment in the company. This strategic partnership involves Lewis Pharmacy issuing new share capital in exchange for a substantial cash investment from OFC, strengthening Lewis Pharmacy's financial position and flexibility. The investment will accelerate Lewis Pharmacy's growth plans in the Europe, the Middle East and Africa region, supporting the expansion of its biosimilars portfolio, manufacturing capabilities, and supply chain resilience. Key figures like Ghiath Sukhtian, Chairman of Lewis Pharmacy, Kalle Känd, CEO of Lewis Pharmacy, and Nabeel Al-Amudi, CEO of Olayan Financing Company, expressed optimism about the partnership. The collaboration also reinforces Lewis Pharmacy's commitment to localization under the Saudi National Biotechnology Strategy and Saudi Vision 2030, especially in Saudi Arabia where its biologics site received SFDA GMP approval.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard